Alkermes: Demonstrating Value
You may also be interested in...
ACA Perspectives: Alkermes Looks For Boon From Expanded Mental Health Benefits
Alkermes’ focus on mental illnesses, substance abuse and other CNS disorders could gain a boost from essential health benefit and mental health parity provisions of the law.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.